The Liver INSPECTR Trial: Towards improved understanding of liver function following radiotherapy

Authors

Nicholas G. Hardcastle, University of Wollongong, Peter MacCallum CancerFollow
Carol Haddad, Royal North Shore Hospital
G Schembri, Royal North Shore Hospital
D Bailey, Royal North Shore Hospital
B Jones, Royal North Shore Hospital
Adam Briggs, Royal North Shore HospitalFollow
George Hruby, Royal North Shore Hospital
Andrew Kneebone, Royal North Shore Hospital

RIS ID

135217

Publication Details

Hardcastle, N., Haddad, C., Schembri, G., Bailey, D., Jones, B., Briggs, A., Hruby, G. & Kneebone, A. (2019). The Liver INSPECTR Trial: Towards improved understanding of liver function following radiotherapy. Journal of Physics: Conference Series, 1154 (Conference 1), 1-4.

Abstract

Liver stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for primary liver cancer and liver metastases. Liver SABR can provide high rates of local control however tumour doses are limited by dose to surrounding organs at risk including liver and gastrointestinal structures. Dose limits to liver are based on anatomical liver, without understanding of underlying liver function. This report describes a prospective clinical trial which measures the spatial variance of liver function through Tc-99m Mebrofenin SPECT in the context of liver SABR.